Randomized phase III trial of Docetaxel versus docetaxel plus S-1 for second-line treatment of non-small cell lung cancer (NSCLC)

INTERVENTION: Docetaxel alone Docetaxel and S‐1 CONDITION: Advanced non‐small cell lung cancer PRIMARY OUTCOME: Overall survival SECONDARY OUTCOME: Progression free survival; Adverse events; Response rate INCLUSION CRITERIA: 1) Histologically confirmed Non Small Cell Lung Cancer 2) Advanced Stage (IV or IIIB) 3) With measurable lesion 4) One more prior platinum‐based chemotherapy 5) Performance Status (ECOG) 0‐1 6) )20<=,<75 years 7) Adequate organ functions 8) Patients who have estimated life expectancy longer than 3 month 9) Oral intake is possible 10) Written informed consent